<qa>  What is the main objective of the study?PaxceedTM is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of Rheumatoid Arthritis RA. The main objective of this study is to determine the effectiveness of treatment with PaxceedTM in patients with RA. In RA, there is an increase in cell growth and changes in cell function. The active substance in PaxceedTM, paclitaxel, has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks certain types of cell function associated with RA. Because of these effects, it is thought that PaxceedTM might alter the destructive course of RA. 